Extending to the south from central Europe into the Mediterranean Sea, the region of the Balkans includes the countries of Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Romania, Serbia, Slovenia, The Former Yugoslav Republic of Macedonia (FYR Macedonia), Montenegro. Some of these countries are... Read more
Armenia's pharmaceutical sector is one of the country's most dynamic sectors.
It has become a strategic sector for growing Armenian economy due to both its growing export potential and investment attraction.
Over 10 years from 2005 to 2015 Armenian pharmaceutical sector's production volume... Read more
Kazakhstan's pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia. In terms of market size, its potential is limited by its relatively small population (15mn) and logistical challenges.
In the short term, Kazakhstan's mark... Read more
Azerbaijan pharmaceutical market is by 97% dependent on imports, while the retail price of these products is much higher than in neighboring countries. This is according to local and foreign sources.
According to The Medical Research Pharmexpert in 2013, retail sales of pharmaceutical products in... Read more
For decades, Albania’s public health sector has struggled with the supply and quality of the drugs available on the market. According to a World Bank report published in June 2014, public spending on healthcare in Albania accounts for only 2.6 per cent of GDP, the lowest rate in the region. At the ... Read more
The Serbian pharmaceutical market is being constrained by a focus on cost-containment and drug prices by the RFZO with a drive towards fiscal consolidation by the Serbian government. The worsening macroeconomic outlook for the Serbian economy in 2015 and 2016 will have a tangible effect on household... Read more
Pharmaceutical market in Russia is rapidly growing. Annually its volume increases by about 14-15%. On the world stage, Russia ranks 11th in average use of medicines.
Companies providing services in the area of pharma regulatory affairs in Russia, work with such authoritative bodies as the Governm... Read more
According to BMI market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Pharmaceutical market is estimated at €338mn in 2015 and healthcare expenditure at € 970 mn. The de... Read more
The Lithuanian pharmaceutical market is estimated at € 601million. According to BMI non-communicable conditions such as cardiovascular disease and cancer dynamics will make the country attractive to innovative drug-makers. In 2010-2015 Lithuania’s economy has been steadily growing and in 2014 and in... Read more
The Croatian pharmaceutical market is currently worth around €740.1 million. In the short term, the market is considered challenging for manufacturers of branded products because of the prevalence and popularity of generic drugs, and strict reimbursement criteria. However, in the longer term there a... Read more
In 2014, Romania’s market size increased by 6.8 percent to € 2.76 billion with Romanians OTC drugs to the tune of some € 755 million in the final quarter 2015 alone, reflecting an 11.8 percent year-on-year rise, according to market research conducted by Cegedim. Meanwhile the country’s newly appoint... Read more
There appears to be paucity of accurate national statistics as far as the size of the pharmaceutical market in Georgia is concerned. 2016 market value estimates vary between $278mn and $365mn. Import and consumption of pharmaceutical products in Republic of Georgia are increasing yearly. Compound A... Read more
The pharmaceutical sales were estimated at €289mn in 2014 and forecast to grow to €307mn in 2015. The national healthcare expenditure was valued at €1.12bn in 2014 and is forecast to reach €1.19bn in 2015. Read more
Slovenia's healthcare system is relatively developed and effective, particularly compared with other markets in Central and Eastern Europe. The country's health system faces short-term challenges as a result of austerity budgets which will limit public spending on healthcare and are designed to redu... Read more
The healthcare expenditure in Slovakia was valued at €6.08bn in 2014 and is forecast at €6.29bn in 2015. Slovakia’s market for ppharmaceutical products totalled €1.85bn in 2014 and is estimated to reach €1.91bn in 2015 (source: BMI Research). The consumption of reimbursed drugs in Slovakia stood at ... Read more
Although small, the Bulgarian pharmaceutical market is showing strong growth. Medicines comprise not only a disproportionate share of health care expenditure (38% of total health expenditure, compared with an EU average of around 25%), the out of pocket (OOP) costs are also excessive, estimated at 8... Read more
BMI View: Hungary's pharmaceutical market represents a moderate but reliable commercial prospect within Central and Eastern Europe. The government plays a key role in the provision of medical services as demonstrated by its recent ban on parallel exports of medicines and the decentralization of prim... Read more
Poland is the largest pharmaceutical market in the Central & Eastern Europe region and the sixth largest in Europe (€ 6.1 billion in market value). With a GDP growth of 3% forecast by the OECD for 2016, there are also clear signs of economic momentum. However, Poland has some of the lowest price... Read more
The Czech Republic is ranked as the second most attractive market in the Central and Eastern Europe – beaten only by Poland. It is also home to several world-class R&D centers and is the 3rd largest market for clinical trials in the region. “The Czech healthcare system includes a diversity of pr... Read more